- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07627984
Cerebral Embolic Protection Device During TAVR
2 juni 2026 uppdaterad av: Shanghai Shenqi Medical Technology Co., Ltd
A Prospective, Multicenter, Randomized Controlled Clinical Trial to Evaluate the Safety and Efficacy of a Cerebral Embolic Protection Device for Capturing and Removing Thrombus/Tissue Debris During Transcatheter Aortic Valve Replacement
To evaluate the safety and effectiveness of the Cerebral Protection System (model CEP016F, Shanghai Shenqi Medical Technology Co., Ltd.) for capturing and removing thrombotic and tissue debris during transcatheter aortic valve replacement (TAVR).
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This study is a prospective, multicenter, randomized controlled clinical trial designed to evaluate the safety and effectiveness of the Cerebral Protection System (model CEP016F, Shanghai Shenqi Medical Technology Co., Ltd.) for capturing and removing thrombotic and tissue debris during transcatheter aortic valve replacement (TAVR).
The target study population includes adult patients who are suitable for TAVR using commercially available domestic transcatheter aortic valve systems and whose vascular anatomy is appropriate for placement of the device in the brachiocephalic artery and left common carotid artery.
The planned sample size is 260 subjects.
Eligible subjects will be randomized in a 1:1 ratio to the device group (TAVR with the cerebral protection system) or the control group (TAVR without the device) using a centralized stratified randomization system based on valve type (self-expanding or balloon-expandable).
All subjects are planned to undergo follow-up within 24 hours after procedure, at 2±1 days, at 48-72 hours or before discharge (whichever comes first), and at 30 days after TAVR.
Studietyp
Interventionell
Inskrivning (Faktisk)
260
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
Xiamen, Kina
- Xiamen Cardiovascular Hospital Xiamen University
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Nej
Beskrivning
Inclusion Criteria:
- Age ≥18 years, male or non-pregnant/non-lactating female.
- Suitable for TAVR and planned to undergo TAVR using an approved transcatheter aortic valve system.
- TAVR access limited to transfemoral or transapical approach.
- Imaging-confirmed left common carotid artery diameter of 6.5-10 mm and brachiocephalic artery diameter of 9-15 mm at the site of filter placement.
- No severe stenosis (>70%), dilation, dissection, ostial aneurysm, or aneurysm within 3 cm of the aortic origin in the target vessels.
- Brain imaging evaluable by 3-Tesla magnetic resonance imaging.
- Willing to comply with protocol-required follow-up assessments.
- Written informed consent provided by the subject or legal guardian.
Exclusion Criteria:
- Impaired right upper limb blood flow.
- Intracranial hemorrhage, stroke, or transient ischemic attack within 6 months before procedure.
- Acute myocardial infarction within 1 month before procedure.
- Calcification in the intended filter deployment region.
- Planned pacemaker or defibrillator implantation within 30 days after TAVR.
- Left ventricular ejection fraction ≤20%.
- Infective endocarditis, intracardiac/aortic mass, thrombus, or vegetation on echocardiography.
- Severe occlusive carotid disease requiring concomitant carotid intervention, or carotid stenting/endarterectomy within 6 weeks.
- Leukopenia, acute anemia, thrombocytopenia, bleeding diathesis, or coagulation disorder.
- Active peptic ulcer disease or gastrointestinal bleeding within 3 months.
- Severe allergy or known contraindication to nitinol, stainless steel alloy, or contrast media.
- Contraindication to antiplatelet and/or anticoagulation therapy, or refusal of blood transfusion.
- Severe renal insufficiency (serum creatinine >3.0 mg/dL, eGFR <30 mL/min, or need for renal replacement therapy).
- Known psychiatric disease or substance abuse that may interfere with compliance or data interpretation.
- Life expectancy <1 year.
- Active infection requiring concurrent antibiotic therapy.
- Other clinical conditions preventing compliance with the instructions for use of the investigational device.
- Concurrent use or planned use of another investigational device or drug during the study period.
- Severe tortuosity of right upper extremity vessels or inability to accommodate a 6 F sheath.
- Contraindication to MRI, including implanted pacemaker/defibrillator, metal implants, metal fragments, clips, or intracranial/ocular implanted devices.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Use of a cerebral embolic protection device during TAVR
|
The cerebral embolic protection device is a percutaneously delivered dual-filter protection device designed to capture and remove dislodged debris during transcatheter aortic valve replacement (TAVR).
The system utilizes one filter delivered to the brachiocephalic trunk (proximal filter) and a second filter delivered to the left common carotid artery (distal filter).
Upon completion of the procedure, the filters and debris are retrieved back into the catheter and removed from the patient.
|
|
Inget ingripande: TAVR without the use of a cerebral embolic protection device
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
The median total volume of new lesions within the protected brain territories, as assessed by diffusion-weighted magnetic resonance imaging (DW-MRI) at 2±1 days after TAVR.
Tidsram: At 2±1 days after TAVR.
|
Protected brain territories are defined as the cerebral regions perfused exclusively by the vessels protected by the cerebral embolic protection device, namely the brachiocephalic artery and the left common carotid artery.
Total volume of new lesions is defined as the sum of all newly detected diffusion-positive brain lesions on post-TAVR DW-MRI relative to pre-TAVR DW-MRI.
|
At 2±1 days after TAVR.
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
20 september 2023
Primärt slutförande (Faktisk)
16 april 2025
Avslutad studie (Faktisk)
16 april 2025
Studieregistreringsdatum
Först inskickad
22 maj 2026
Först inskickad som uppfyllde QC-kriterierna
2 juni 2026
Första postat (Faktisk)
4 juni 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
4 juni 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
2 juni 2026
Senast verifierad
1 juni 2026
Mer information
Termer relaterade till denna studie
Nyckelord
Andra studie-ID-nummer
- CEPD01-001
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .